This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
Other/Multi
ASCO 2025 | May 30-June 3,2025
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors
Poster
T-DXd
ASCO 2025 | May 30-June 3,2025
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy ±
pembrolizumab versus chemotherapy + trastuzumab ± pembrolizumab in first-line metastatic HER2+ gastric
or gastroesophageal junction cancer: DESTINY-Gastric05
Poster
T-DXd
ASCO 2025 | May 30-June 3,2025
ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan as first-line treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer
Poster
T-DXd
ASCO 2025 | May 30-June 3,2025
Electronic patient-reported outcomes with vital signs monitoring versus usual care during trastuzumab deruxtecan treatment for metastatic breast cancer: Updated results from the PRO-DUCE study
Oral
T-DXd
ASCO 2025 | May 30-June 3,2025
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06
Poster
Dato-DXd
ASCO 2025 | May 30-June 3,2025
First-line datopotamab deruxtecan
(Dato-DXd) + rilvegostomig in advanced
or metastatic non-small cell lung cancer:
Results from TROPION-Lung04 (cohort 5)
Poster
HER3-DXd
ASCO 2025 | May 30-June 3,2025
HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant
patritumab deruxtecan (HER3-DXd) plus pembrolizumab before or after pembrolizumab plus
chemotherapy for early-stage triple-negative breast cancer (TNBC) or hormone receptor–low
positive (HR-low+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer
Poster
I-DXd
ASCO 2025 | May 30-June 3,2025
IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with recurrent or metastatic solid tumors
Poster
I-DXd, HER3-DXd
ASCO 2025 | May 30-June 3,2025
KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer
Poster
I-DXd
ASCO 2025 | May 30-June 3,2025
KEYMAKER-U06 Substudy O6E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma
Pages:
1 2